TP53 and cancer: The main findings of this study were that daily supplementation of 2000 IU of vitamin D reduced the risk of relapse or death by 27% compared with placebo in the p53-immunoreactive subgroup, defined by positivity for p53-Ab in serum and p53 protein in more than 99% of cancer cells.